Viracta Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Viracta Therapeutics, Inc. - overview
Established
2007
Location
-, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2007, Viracta Therapeutics, Inc. , formerly known as HemaQuest Pharmaceuticals, Inc. is a precision oncology company that focuses on virus-related diseases. Ivor Royston, M.
D. , is the current President and Chief Executive Officer of the company. In 2020, Sunesis Pharmaceuticals, Inc. merged with the company, and in February 2021, Viracta Therapeutics raised USD 65 million in PIPE funding led by new investor BVF Partners, with participation from other new investors.
The company offers a combination approach to treat a range of viral-associated cancers and other serious diseases. Viracta’s proprietary investigational drug called nanatinostat in combination with the antiviral agent valganciclovir is a novel therapeutic approach to targeting EBV+ lymphoma. The company is also looking at using its inducible synthetic lethality technique in other EBV-related diseases, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers. Following the merger with Sunesis Pharmaceuticals, the company intends to continue advancing and expanding Viracta's clinical-stage pipeline, including Viracta's lead program for the treatment of Epstein-Barr virus (EBV)-positive lymphoma.
Current Investors
Forward Ventures, Latterell Venture Partners, Wicklow Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.viracta.com
Total Amount Raised
Subscriber access only
Viracta Therapeutics, Inc. - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 5,000,000 | 3,754,000 | 7,956,000 | 5,734,000 | 3,061,000 | 2,536,000 | 669,000 | 237,000 | 2,073,000 | 120,000 | - | - | - |
| % Revenue Growth (YoY) | - | (24.9%) | 111.9% | (27.9%) | (46.6%) | (17.2%) | (73.6%) | (64.6%) | 774.7% | (94.2%) | - | - | - |
| EBITDA (USD) | (25,754,000) | (34,175,000) | (31,132,000) | (44,647,000) | (39,140,000) | (36,090,000) | (34,141,000) | (25,509,000) | (23,242,000) | (22,309,000) | - | - | - |
| Operating Income (USD) | (25,866,000) | (34,606,000) | (31,773,000) | (45,043,000) | (39,302,000) | (36,460,000) | (34,419,000) | (25,710,000) | (23,288,000) | (22,303,000) | - | - | - |
| Operating Margin | (517.3%) | (921.8%) | (399.4%) | (785.5%) | (1284.0%) | (1437.7%) | (5144.8%) | (10848.1%) | (1123.4%) | (18585.8%) | - | - | - |
| % EBITDA Margin | (515.1%) | (910.4%) | (391.3%) | (778.6%) | (1278.7%) | (1423.1%) | (5103.3%) | (10763.3%) | (1121.2%) | (18590.8%) | - | - | - |
| NET Income (USD) | (20,141,000) | (43,951,000) | (34,598,000) | (43,002,000) | (36,676,000) | (38,023,000) | (35,458,000) | (26,615,000) | (23,330,000) | (21,610,000) | - | - | - |
| % Net Margin | (402.8%) | (1170.8%) | (434.9%) | (749.9%) | (1198.2%) | (1499.3%) | (5300.1%) | (11230.0%) | (1125.4%) | (18008.3%) | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.